StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $1.55 | $1.51 | -2.58% | 0.2M |
| 05-15 | $1.50 | $1.35 | -10.00% | 0.3M |
| 05-18 | $1.38 | $1.43 | +3.62% | 0.2M |
| 05-19 | $1.41 | $1.49 | +5.67% | 0.2M |
| 05-20 | $1.54 | $1.49 | -3.25% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for ALLR yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $25.00K | $320.00K | $0.00 | $0.00 |
Operating Income | $-2.69M | $-12.61M | $-3.04M | $-27.24M |
Net Income | $-2.75M | $-11.23M | $-2.73M | $-24.52M |
EPS (Diluted) | $-0.17 | $-0.78 | $-0.25 | $-15.65 |
Total Assets | $34.92M | $18.26M | $29.73M | $22.65M |
Total Liabilities | $28.00M | $8.43M | $11.06M | $10.84M |
Cash & Equivalents | $19.81M | $14.69M | $25.20M | $19.53M |
Free Cash Flow OCF − CapEx | $-4.56M | $-14.83M | $-2.69M | $-17.65M |
Shares Outstanding | 15.82M | 16.08M | 17.02M | 7.30M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.